RxDoctor Payments Data

Robert Fraser, MD

Cardiovascular Disease · Minneapolis, MNNPI 1508109786

Payments from drug & device makers

$160,066in general payments, 2019–2025

Across 28 payments — averaging $5716.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$159K
  • Abbott$1K
  • Bristol Myers Squibb$300
  • Heartflow, Inc.$16

What the payments were for

  • Consulting fees$7,92062%
  • Speaking & faculty fees$3,76529%
  • Food & beverage$1,1629%
  • Education$60%

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
E.r. Squibb & Sons, L.L.C.15$158,687
Abbott11$1,062
Bristol Myers Squibb1$300
Heartflow, Inc.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$160,066 in reported general payments places this provider in the 85th percentile of 451 cardiovascular disease providers in Minnesota.

See all cardiovascular disease providers in Minnesota

Medicare billing

Part B allowed, 2024
$147,845
Medicare patients
1,316
Services billed
2,444

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CamzyosMavacamten128$1,051,798
EliquisApixaban297$391,390
VyndamaxTafamidis17$368,570
XareltoRivaroxaban145$162,178
EntrestoSacubitril/Valsartan39$55,523
JardianceEmpagliflozin38$43,995
Repatha SureclickEvolocumab24$32,378
OzempicSemaglutide22$21,873
WegovySemaglutide16$21,184
FarxigaDapagliflozin Propanediol12$18,314
Praluent PenAlirocumab14$11,893
Metoprolol Succinate466$8,223
Atorvastatin Calcium322$3,891
Ezetimibe109$2,588
SotalolSotalol Hcl126$2,559

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Camzyos$158,687$1,051,798128 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 451 cardiovascular disease providers in Minnesota.

Other cardiovascular disease in Minneapolis

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →